News

Revolutionising orthopaedic revision surgery: An innovative approach to major joint implant revisions

November 13, 2023
Anouk Dagelet
News

Researchers at the Orthopedic department of the UMC Utrecht developed a device that can remove bone cement during implant revision surgery.

A patient specific approach is achieved by making use of 3D printing for the surgical guide and a precision bone cement removal tool. The invention has been patented and a first proof of concept was developed at the UMCU. Utrecht Holdings has recently exclusively licensed the technology to start-up company Amotio BV who will be working on further development and commercialization of the invention. Amotio BV was established and guided by NLC, a venture builder specialized in the field of healthcare.

Amotio BV has already completed early concept testing and market evaluation. The next phase includes robust product development and clinical evaluation, leading to medical device registration in key global markets and a planned commercial launch.

More info on Amotio Orthopedic Revision Surgery

Below the pressrelease of NLC:

Amsterdam & Cardiff, 13 November 2023

Led by CEO Iestyn Foster, Amotio is on a mission to transform the way joint implant revision surgery is conducted.

By 2030, an estimated 1.4 billion individuals will be the beneficiaries of hip, knee and shoulder implants. Unfortunately, approximately 7% of these implants require revisions and replacement resulting in a substantial burden for both patients and healthcare providers.

Amotio offers a new approach for improved implant revision surgery; their innovative solutions are designed to optimise patient outcomes by developing unique bone cement removal devices, integrated with advanced patient specific 3D surgical planning and printing technology. The aim is to set a new standard for excellence in cemented implant revision surgery.

Iestyn Foster, Amotio CEO: ‘Our commitment resonates globally as we strive to lead pioneering advances which elevate patient outcomes and alleviate the burdens of surgery enabling people to improve their mobility and quality of life following major joint revision surgery.’

In collaboration with a team of expert revision surgeons, Utrecht University Medical Centre and guided by NLC, the European Healthcare Venture Builder, Amotio has secured an exclusive licensing agreement to lead the product development and market entry. Now in its pre-seed funding phase, the company is seeking strategic investors.

Amotio has targeted their early market launch strategy within the Netherlands and UK, followed by expansion into Germany and the Benelux countries. Further phases will unfold in the regions of North America, Europe, APAC, and MEA.

About NLC- The European Healthtech Venture Builder

Pain monitoring systems, ultrasound cancer detection, light therapy for newborns: these are just some of the life-changing inventions that we have brought to those in need. Rooted in the Netherlands, NLC – The European Healthtech Venture Builder has nurtured over 100 healthtech startups since 2015.

FOR MORE INFORMATION
NLC – The European Healthtech Venture Builder
Anne Reijns
Marketing & Communications Lead
anne.reijns@nlc.health

Amotio
Iestyn Foster – CEO